Augmenting tumor uptake of Tc-99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon

Li, J; Thakur, M L; Wilder, S

Title: Augmenting tumor uptake of Tc-99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon

Full Record
Other Related Research

Abstract

Following the evaluation of radiolabeled MAbs for scintigraphic imaging or therapy, low tumor uptake emerged as one of the most prominent problems. The aim of this investigation was to examine the influence of interferon (IFN)-{alpha}2b in augmenting uptake of Tc-99m labeled antimelanoma MAb 31.3 in nude mice bearing experimental human melanoma. MAb was labeled with Tc-99m by our ascorbic acid mediated reduction technique, analyzed and 20 {mu}g containing 40-120 {mu}Ci Tc-99m were administered i.v., 1 hr following i.m. or i.v. administration of 10K, 20K, or 100K i.u. IFN-{alpha}2b. Animals receiving 0.9% saline similarly served as controls. 4 and 24 hrs later, animals were sacrificed, imaged, and dissected for tissue distribution studies. Tumor blood flow was measured before and after administration of IFN by color Doppler imaging technique, intratumoral temperature was recorded using thermocouples, and tumor histology was performed to visualize tumor lymphocytic infiltration. Although no excessive lymphocytic infiltration was seen within 72 hr post-injection of IFN, and only a modest increase in tumor temperature was noted, a significant increase in blood flow was observed within 45 min. as differentiated by amplitudes at peak systolic and end diastolic cardiac cycles. The best tumor uptake enhancement was noted at 24 hr followingmore »« less

Authors:

Li, J; Thakur, M L; Wilder, S ^[1]

Thomas Jefferson Univ. Hospital, Philadelphia, PA (United States); and others

Publication Date:: Sun May 01 00:00:00 EDT 1994

OSTI Identifier:: 197959

Report Number(s):: CONF-940605-
Journal ID: JNMEAQ; ISSN 0161-5505; CNN: Grant NIHCA51960; TRN: 95:007029-0099

Resource Type:: Journal Article

Journal Name:: Journal of Nuclear Medicine

Additional Journal Information:: Journal Volume: 35; Journal Issue: Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994

Country of Publication:: United States

Language:: English

Subject:: 55 BIOLOGY AND MEDICINE, BASIC STUDIES; TECHNETIUM 99; UPTAKE; MELANOMAS; DIAGNOSTIC TECHNIQUES; RADIOTHERAPY; BLOOD FLOW; HISTOLOGY; INTERFERON; MONOCLONAL ANTIBODIES; TISSUE DISTRIBUTION; IMAGES; MICE

Citation Formats


                    Li, J, Thakur, M L, and Wilder, S. Augmenting tumor uptake of Tc-99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon.  United States: N. p., 1994. 
        Web.

Copy to clipboard


                    Li, J, Thakur, M L, & Wilder, S. Augmenting tumor uptake of Tc-99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon.  United States.

Copy to clipboard


                    Li, J, Thakur, M L, and Wilder, S. 1994.  
        "Augmenting tumor uptake of Tc-99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon".  United States.

Copy to clipboard


                    
@article{osti_197959,

  title        = {Augmenting tumor uptake of Tc-99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon},

  author       = {Li, J and Thakur, M L and Wilder, S},

  abstractNote = {Following the evaluation of radiolabeled MAbs for scintigraphic imaging or therapy, low tumor uptake emerged as one of the most prominent problems. The aim of this investigation was to examine the influence of interferon (IFN)-{alpha}2b in augmenting uptake of Tc-99m labeled antimelanoma MAb 31.3 in nude mice bearing experimental human melanoma. MAb was labeled with Tc-99m by our ascorbic acid mediated reduction technique, analyzed and 20 {mu}g containing 40-120 {mu}Ci Tc-99m were administered i.v., 1 hr following i.m. or i.v. administration of 10K, 20K, or 100K i.u. IFN-{alpha}2b. Animals receiving 0.9% saline similarly served as controls. 4 and 24 hrs later, animals were sacrificed, imaged, and dissected for tissue distribution studies. Tumor blood flow was measured before and after administration of IFN by color Doppler imaging technique, intratumoral temperature was recorded using thermocouples, and tumor histology was performed to visualize tumor lymphocytic infiltration. Although no excessive lymphocytic infiltration was seen within 72 hr post-injection of IFN, and only a modest increase in tumor temperature was noted, a significant increase in blood flow was observed within 45 min. as differentiated by amplitudes at peak systolic and end diastolic cardiac cycles. The best tumor uptake enhancement was noted at 24 hr following i.m. administration of 20K i.u. IFN and measured greater than 300% of the control value (7.2{plus_minus}1.2%/g vs. 2.2{plus_minus}1.4%/g). IFN-{alpha}2b enhances tumor blood flow in experimental tumors and significantly augments the uptake of radiolabeled MAbs.},

  doi          = {},

  url          = {https://www.osti.gov/biblio/197959},
  journal      = {Journal of Nuclear Medicine},
number       = Suppl.5,

  volume       = 35,

  place        = {United States},

  year         = {Sun May 01 00:00:00 EDT 1994},

  month        = {Sun May 01 00:00:00 EDT 1994}

}

Copy to clipboard

Journal Article:

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Tc-99m labeled anti CEA F(ab{prime}){sub 2}: Augmenting tumor uptake with anitbody:Interferon (MAb:IFN-{alpha}-2b) conjugate

Journal Article Thakur, M; Donegan, M; Li, J - Journal of Nuclear Medicine

Previously we have shown that IFN-{alpha}-2b, a potent biological response modifier (BRM) significantly enhanced tumor uptake of radiolabeled MAbs. Results were attributed to increased blood flow and upregulation of cell surface receptor glycoproteins. Probably because of the blood flow increase in all organs, radioactivity levels in other tissues, although to a lesser extent, were also enhanced. In order to validate our hypothesis that selective tumor targeting of IFN-{alpha}-2b (Schering-Plough, N.J.) may enhance tumor uptake and diminish uptake in normal organs, IFN-{alpha}-2b was conjugated with anti CEA MAb F-6 (IgG2a), by reacting with 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate (CMC) and N-hydroxysulfosuccinimide (NHS) in amore »« less
Novel antibody conjugates for enhanced tumor uptake. Final report, September 1, 1992--August 31, 1997

Technical Report Thakur, M

Progress in three areas of research is summarized. These are as follows: Labeling Monoclonal antibodies (MAbs) with Tc-99m and Re-186; human melanoma tumors and specific MAbs; evaluation of biological response modifiers (BRM). The techniques of labeling MAbs (IgM, IgG, F(ab{prime}){sub 2} or F(ab{prime})) with Tc-99m was developed in the author`s laboratory in 1989 and that with Re-186 in 1992. The techniques are in daily use in the laboratory since then and are adapted to a convenient kit formulation. The metal ions are bound at MAb sulfhydryls generated by a controlled reduction of a pair of disulfide groups. At least twomore »« less
https://doi.org/10.2172/674916

Full Text Available
Biodistribution pharmacokinetics and radiation dosimetry of Tc-99m D-glucaric acid in humans

Journal Article Molea, N; Bodei, L; Lazzeri, E - Journal of Nuclear Medicine

Previous experimental studies have shown the high targeting potential of Tc-99m-labeled D-glucaric acid (TcGLA, a six-carbon dicarboxylic acid partly competing in vitro with fructose/glucose uptake) in animal models of acute ischemia/early necrosis of the heart or brain, and in human tumor xenografts. This study evaluated the biodistribution pharmacokinetics and radiation dosimetry of TcGLA in cancer patients. TcGLA (900 MBq) was injected i.v. as a bolus into 12 patients with breast (n=9) or colon (n=3) cancer. Whole-body scans were recorded at 0.5, 1,2,4,6, 10,24,32,46 hr while blood samples were taken at frequent intervals and urines were collected at 6-hr intervals. Themore »« less
In vivo tumor localization of technetium-labeled metalothionein/monoclonal antibody conjugates

Conference Tolman, G; Hadjian, R; Morelock, M; ... - J. Nucl. Med.; (United States)

The use of radioiodinated monoclonal antibodies (MAb) directed against tumor associated antigens for imaging has reinforced the need for additional labeling methods to permit the use of other medically relevant radionuclides. The low molecular weight metal binding protein, metallothionein (MT) has a high avidity for several radionuclides including Tc-99m. The conjugation of a Zn-MT to MAb B6.2 directed against human breast carcinoma was studied using glutaraldehyde as the bifunctional cross-linker. The Zn-MT-B6.2 conjugate was labeled with Tc-99m to form a Tc-99m labeled MT-B6.2 conjugate. Radiolabeled conjugates were shown to retain high immunoreactivity compared to radio-iodinated B6.2 in a direct cellmore »« less
Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects

Journal Article Vallabhajosula, S; Zimmerman, R; Picard, M; ... - J. Nucl. Med.; (United States)

Lipophilic neutral /sup 99m/Tc complexes of diaminedithiol (DADT) ligands cross the brain-blood barrier. A new derivative of DADT family, /sup 99m/Tc ethyl cysteinate dimer (ECD) showed high brain uptake in nonhuman primates. We report here the in vivo kinetics and biodistribution results in 16 normal human subjects. Dynamic images of brain obtained for 10 min following an i.v. administration of (/sup 99m/Tc)ECD showed that the maximum /sup 99m/Tc brain activity reached within 1 min and remained near that level for the next 10 min. The blood clearance of the tracer was very rapid and the activity remaining in blood aftermore »« less

Similar Records